Q-omics provides the consensus-scored EEF1B2P7 profile across patient tissues and cancer cell-line models. EEF1B2P7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EEF1B2P7 is differentially expressed in 4, with the highest sampling consensus in CHOL. Additionally, EEF1B2P7 RNA expression shows 12,332 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, CHOL, and UVM as cancer lineages where EEF1B2P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EEF1B2P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EEF1B2P7 survival associations across molecular data types. EEF1B2P7 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EEF1B2P7 RNA expression–survival associations across cancer types. High EEF1B2P7 expression shows unfavorable associations in ACC, KIRC, UVM and UCEC, but favorable associations in UCS and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EEF1B2P7 RNA expression.
This table summarizes EEF1B2P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for EEF1B2P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EEF1B2P7 shows lower tumor expression in LIHC and higher tumor expression in CHOL, LIHC, HNSC and ESCA. The CHOL box plot shows higher EEF1B2P7 RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p = .011).
This table shows molecular features associated with EEF1B2P7 in patient tissues and cancer cell lines. In patient samples, EEF1B2P7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
